Skip to content

Comparison of the serum ferritin level with diabetic and non-diabetic Covid-19 patients.

FERRITIN - THE KEY MODEL INFLAMMATORY MARKER IN DIABETIC AND NONDIABETIC COVID 19 PATIENTS A RETOSPECTIVE STUDY

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/04/032619
Enrollment
400
Registered
2021-04-07
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

None listed

Sponsors

Mukesh Kumar
Lead Sponsor
MUKESH KUMAR
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: All type II Diabetic patients based on ADA criteria.

Exclusion criteria

Exclusion criteria: 1) Type 1 diabetes mellitus 2) Conditions that altered serum ferritin levels like: Hemochromatosis, Chronic alcoholics, chronic inflammatory conditions like SLE/ rheumatoid arthritis, Hepatitis, History of repeated blood transfusions, Iron deficiency anemia, Hypothyroidism, Chronic kidney disease.

Design outcomes

Primary

MeasureTime frame
The Diabetic faces high probability to extreme serious complication from Covid -19 than non-diabetics. This study will help in the correlation between elevated serum ferritin with blood glucose level in Covid-19 diabetic patients during the treatment and also to rule out whether decreasing serum ferritin and controlling blood glucose helps in the betterment of Covid-19 patients.Timepoint: six months

Secondary

MeasureTime frame
this study will also help to rule out whether decreasing serum ferritin and controlling blood glucose helps in the betterment of Covid-19 diabetes mellitus type 2 patients during the entire hospitalization period. On this basis, we can briefly review evidence supporting the hypothesis that ferritin and blood glucose level might be the crucial factor influencing the severity of COVID-19Timepoint: six months

Countries

India

Contacts

Public ContactMukesh Kumar

Rajarajeswari medical college and research center

sehrajmsmile2007@gmail.com7259215100

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026